RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Perl, A; Altman, J; Cortes, J; Levis, M; Smith, C; Litzow, M; Baer, MR; Claxton, D; Erba, H; Gill, S; Goldberg, S; Jurcic, J; Larson, RA; Liu, C; Ritchie, E; Sargent, B; Schiller, G; Spira, A; Strickland, S; Tibes, R; Ustun, C; Wang, ES; Stuart, R; Bahceci, E

Published Date

  • June 1, 2015

Published In

Volume / Issue

  • 100 /

Start / End Page

  • 317 - 318

Published By

Pages

  • 2

International Standard Serial Number (ISSN)

  • 0390-6078

Conference Name

  • 20th Congress of European-Hematology-Association

Conference Location

  • Vienna, AUSTRIA

Conference Start Date

  • June 11, 2015

Conference End Date

  • June 14, 2015